AntiGPC3-PB NPs (antiglypican3-Prussian Blue Nanoparticles) for photothermal therapy and magnetic resonance imaging of liver cancer as well as preparation and application thereof

A technology for photothermal therapy and liver cancer, which is used in MRI/MRI contrast agents, medical preparations without active ingredients, and medical preparations containing active ingredients, etc., to achieve good target recognition function and excellent photothermal killing. Function, effect of good MRI imaging function

Active Publication Date: 2014-05-14
FUZHOU HOSPITAL FOR INFECTIOUS DISEASE
View PDF0 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] After searching relevant patents and literatures, it is found that there is no covalent coupling method to link GPC3 antibody to the surface of PB NPs with citric acid as a protective agent to obtain antiGPC3-PB NPs for liver cancer-specific targeting nuclear magnetic resonance imaging and Related reports on photothermal therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • AntiGPC3-PB NPs (antiglypican3-Prussian Blue Nanoparticles) for photothermal therapy and magnetic resonance imaging of liver cancer as well as preparation and application thereof
  • AntiGPC3-PB NPs (antiglypican3-Prussian Blue Nanoparticles) for photothermal therapy and magnetic resonance imaging of liver cancer as well as preparation and application thereof
  • AntiGPC3-PB NPs (antiglypican3-Prussian Blue Nanoparticles) for photothermal therapy and magnetic resonance imaging of liver cancer as well as preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Accurately weigh 5.4mg of FeCl 3 ·6H 2 O drug, add 20.0mL deionized water to dissolve in a clean three-necked flask to obtain a concentration of 1.0mM FeCl 3 Solution, then add 0.5mmol (ie 98.0mg) of anhydrous citric acid, stir mechanically, and heat to 60°C. Accurately weigh 8.4mg of K 4 [Fe(CN) 6 ]·3H 2 O drug, add 20.0mL of deionized water into a clean beaker with a capacity of 50.0mL and dissolve to obtain a concentration of 1.0mM K 4 [Fe(CN) 6 ] aqueous solution, and then add 0.5mmol (ie 98.0mg) of anhydrous citric acid, stir mechanically, and heat to 60°C.

Embodiment 2

[0040] The prepared 1.0mM K containing 0.5mmol citric acid 4 [Fe(CN) 6 ] aqueous solution at 60°C was slowly added dropwise to the prepared 1.0mM FeCl containing 0.5mmol citric acid 3 In the aqueous solution, with continuous mechanical stirring, it can be found that a clear and bright blue color appears in the mixed solution, indicating that Prussian blue nanoparticles are generated, and the pH of the mixed system is now ~ 2.8. Continue to stir for 30 minutes, cool to room temperature, centrifuge at 30,000 rpm for 15 minutes to collect the precipitate, disperse and wash with deionized water, and repeat this process three times. Finally, the precipitate was collected and vacuum-dried overnight at 50°C to obtain a blue-black dry solid, which was weighed and quantified, and stored in a dry place at room temperature. The surface of the Prussian blue nanoparticles synthesized in this step is modified with citric acid as a protective agent, and citric acid can pass through the car...

Embodiment 3

[0042] Take 4.0 mL of citric acid-modified Prussian blue nanoparticle solution with a concentration of 250 ppm dissolved in PBS buffer solution, and adjust the pH to 5.0 with dilute HCl with a concentration of 0.2N. Accurately weigh 4.0 mg of EDC and 8.0 mg of Sulfo-NHS and add to the above solution successively, and activate at room temperature for 1-2 hours under mechanical vibration.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to antiGPC3-PB NPs (antiglypican3-Prussian Blue Nanoparticles) for photothermal therapy and magnetic resonance imaging of liver cancer as well as preparation and an application thereof. The antiGPC3-PB NPs consist of cores of PB NPs formed by taking citric acid as a surface protectant and a GPC3 antibody which is in covalent coupling through EDC / NHS on the surface. The antiGPC3-PB NPs provided by the invention have a good target recognition function to hepatoma carcinoma cells HepG2 and effectively enter the cells. Meanwhile, the antiGPC3-PB NPs have an excellent photothermal killing function to the HepG2 cells and can be used for photothermal therapy of hepatoma carcinoma cells. The antiGPC3-PB NPs have a good nuclear magnetic resonance contrast imaging function and have a potential of becoming a new generation of a target magnetic resonance imaging contrast agent.

Description

(1) Technical field [0001] The invention relates to a GPC3 antibody-modified Prussian blue nanoparticle (antiGPC3-PB NPs) for photothermal therapy of liver cancer and nuclear magnetic imaging, as well as its preparation method and application. (2) Background technology [0002] Hepatocellular carcinoma (HCC) is one of the most common malignant tumors clinically, and its incidence is increasing year by year. According to statistics, there are about 600,000 new patients with liver cancer every year in the world, and its fatality rate reaches the third place, only slightly behind lung cancer and gastric cancer. my country is the main country with primary liver cancer, accounting for about 55% of the world's new cases every year; in Fujian, liver cancer ranks first among all malignant tumors. The key to cure liver cancer is early detection, early diagnosis and early treatment. Among them, early diagnosis is the key, that is, it can be diagnosed before the clinical symptoms of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K49/06A61K41/00A61K47/48A61K47/34A61P35/00
Inventor 刘小龙刘景丰李正林黄爱民
Owner FUZHOU HOSPITAL FOR INFECTIOUS DISEASE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap